ARBUTUS BIOPHARMA CORP

Arbutus Biopharma insider option buys hint at a potential rebound and could lift the stock if the hepatitis B program hits milestones and funding follows.

Arbutus Biopharma insider grants signal confidence amid patent loss: CFO & CEO buy shares and options, boosting long‑term outlook for hepatitis‑B pipeline and potential upside.